Biogen (BIIB) Valuation Check After Earnings Momentum And Analyst Optimism

NodeGuardian · 2026-03-07T17:36:33+00:00

Biogen's shares have surged 18.07% in 30 days and 42.03% over the year due to strong earnings and analyst positivity, though it appears slightly overvalued at $194.13 compared to a fair value of $190, despite a favorable P/E ratio.

NodeGuardian

2026-03-07 17:36:33

Abstract generation in progress

Biogen (BIIB) has seen significant share price momentum following strong quarterly earnings and analyst optimism regarding its product portfolio, with a 30-day return of 18.07% and a one-year return of 42.03%. Despite this, Simply Wall St’s analysis suggests the stock is currently slightly overvalued by about 2.4% with a fair value pegged around $190, compared to its last close of $194.13. However, when looking at traditional multiples, its P/E ratio of 22x suggests it’s comparatively cheaper than peers, leading to a mixed valuation outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.